The Association of methylprednisolone dosing to cessation of
myotonia in a patient with myotonic dystrophy type 1

J 2020

The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1

HORÁKOVÁ, Magda, Tomáš HORÁK, Josef BEDNAŘÍK a Stanislav VOHÁŇKA

Základní údaje

Originální název

The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1

Autoři

HORÁKOVÁ, Magda (203 Česká republika, domácí), Tomáš HORÁK (203 Česká republika, garant, domácí), Josef BEDNAŘÍK (203 Česká republika, domácí) a Stanislav VOHÁŇKA (203 Česká republika, domácí)

Vydání

Neuromuscular Disorders, London, Elsevier, 2020, 0960-8966

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30103 Neurosciences

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.296

Kód RIV

RIV/00216224:14110/20:00115973

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.nmd.2020.03.004

UT WoS

000539369800009

Klíčová slova anglicky

Myotonia; Myotonic dystrophy; Methylprednisolone; Corticosteroids; Muscle relaxation; Therapy

Štítky

14110221, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 5. 2021 13:11, Mgr. Tereza Miškechová

Anotace

V originále

We report the case of a patient suffering from duplicity of myotonic dystrophy type 1 and ulcerative colitis whose treatment for ulcerative colitis included repeated administrations of descending doses of methylprednisolone and in whom we found an association between methylprednisolone dosing and cessation of myotonia. Myotonia severity was expressed as relaxation time after voluntary contraction and as a patient-reported outcome using the Czech version of the Myotonia Behavior Scale. The patient was being treated for a flare of ulcerative colitis, starting with 32 mg of methylprednisolone and reducing the dose by 4 mg a week. The symptoms of myotonia began to wear off three weeks after starting methylprednisolone and had totally disappeared by four weeks after starting methylprednisolone. The first symptoms of myotonia returned about a month after the last dose of methylprednisolone and reached a peak of severity more than two months after the final dose. (C) 2020 Elsevier B.V. All rights reserved.

Návaznosti

MUNI/A/1325/2019, interní kód MU

Název: Diagnostika a patofyziologie neuropatické bolesti (Akronym: PNB)

Investor: Masarykova univerzita, Diagnostika a patofyziologie neuropatické bolesti, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

MUNI/A/1419/2018, interní kód MU

Název: Diagnostika a patofyziologie neuropatické bolesti (Akronym: PNB)

Investor: Masarykova univerzita, Diagnostika a patofyziologie neuropatické bolesti, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

HORÁKOVÁ, Magda, Tomáš HORÁK, Josef BEDNAŘÍK a Stanislav VOHÁŇKA. The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1. Neuromuscular Disorders. London: Elsevier, 2020, roč. 30, č. 5, s. 427-430. ISSN 0960-8966. Dostupné z: https://dx.doi.org/10.1016/j.nmd.2020.03.004.

@article{1670257,
   author = {Horáková, Magda and Horák, Tomáš and Bednařík, Josef and Voháňka, Stanislav},
   article_location = {London},
   article_number = {5},
   doi = {http://dx.doi.org/10.1016/j.nmd.2020.03.004},
   keywords = {Myotonia; Myotonic dystrophy; Methylprednisolone; Corticosteroids; Muscle relaxation; Therapy},
   language = {eng},
   issn = {0960-8966},
   journal = {Neuromuscular Disorders},
   title = {The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1},
   url = {https://www.sciencedirect.com/science/article/pii/S0960896620300663?via%3Dihub},
   volume = {30},
   year = {2020}
}

TY  - JOUR
ID  - 1670257
AU  - Horáková, Magda - Horák, Tomáš - Bednařík, Josef - Voháňka, Stanislav
PY  - 2020
TI  - The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1
JF  - Neuromuscular Disorders
VL  - 30
IS  - 5
SP  - 427-430
EP  - 427-430
PB  - Elsevier
SN  - 09608966
KW  - Myotonia
KW  - Myotonic dystrophy
KW  - Methylprednisolone
KW  - Corticosteroids
KW  - Muscle relaxation
KW  - Therapy
UR  - https://www.sciencedirect.com/science/article/pii/S0960896620300663?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S0960896620300663?via%3Dihub
N2  - We report the case of a patient suffering from duplicity of myotonic dystrophy type 1 and ulcerative colitis whose treatment for ulcerative colitis included repeated administrations of descending doses of methylprednisolone and in whom we found an association between methylprednisolone dosing and cessation of myotonia. Myotonia severity was expressed as relaxation time after voluntary contraction and as a patient-reported outcome using the Czech version of the Myotonia Behavior Scale. The patient was being treated for a flare of ulcerative colitis, starting with 32 mg of methylprednisolone and reducing the dose by 4 mg a week. The symptoms of myotonia began to wear off three weeks after starting methylprednisolone and had totally disappeared by four weeks after starting methylprednisolone. The first symptoms of myotonia returned about a month after the last dose of methylprednisolone and reached a peak of severity more than two months after the final dose. (C) 2020 Elsevier B.V. All rights reserved.
ER  -

HORÁKOVÁ, Magda, Tomáš HORÁK, Josef BEDNAŘÍK a Stanislav VOHÁŇKA. The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1. \textit{Neuromuscular Disorders}. London: Elsevier, 2020, roč.~30, č.~5, s.~427-430. ISSN~0960-8966. Dostupné z: https://dx.doi.org/10.1016/j.nmd.2020.03.004.

Podrobný výpis o publikaci